TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00960518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adefovir
Description: adefovir at 10 mg daily for 48 weeks

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TACE
Description: An emulsion that consisted of 50 mg of cisplatin and 10 mL of lipiodol at a volume ratio of 1:1 was injected into the blood supply artery of the tumor under fluoroscopic guidance. The injection could be slowed or discontinued if retrograde flow occurred. Embolization was subsequently performed with granules of gelatin sponge particles.
Study: NCT04380857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone ophthalmic insert 0.4 mg
Description: intracanalicular dexamethasone insert

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Prednisolone Acetate Ophthalmic Drops
Description: Topical Prednisolone acetate ophthalmic drops per standard of care:~Every two hours on day of procedure, then four times a day for the first week, then two times a day for the second week, then discontinue
Study: NCT04270825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group CBT with IPT
Description: Group treatment designed to target relationships with both possessions and people.
Study: NCT00990483

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D mammograpgy system
Description: In addition to the standard care diagnostic imaging, all participants underwent two experimental acquisitions, in two projections (Cranio-Caudal and Mediolateral Oblique) on the breast of concern: one acquisition in Mode A (narrow angle acquisition) and one acquisition in Mode B (wide angle acquisition). The experimental imaging is compared to the standard of care imaging
Study: NCT00569686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lovaza
Description: lovaza 4 gm po daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03811730

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography
Description: Eligible patients would be conducted both Transesophageal echocardiography and Transthoracic echocardiography to offer independent results

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Transesophageal echocardiography
Description: Eligible patients would be conducted both Transesophageal echocardiography and Transthoracic echocardiography to offer independent results
Study: NCT01126164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Handbook and Peer Basics
Description: Parent and Peer delivered interventions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Handbook and Peer Basics
Description: Parent and Peer delivered interventions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Handbook and Peer Basics
Description: Parent and Peer delivered interventions
Study: NCT03538340

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Epidural
Description: The control arm will receive standard of care pain management which includes a Thoracic Patient Controlled Epidural

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Epidural
Description: The control arm will receive standard of care pain management which includes a Thoracic Patient Controlled Epidural

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intercostal Cryoanalgesia
Description: The study arm will receive standard of care pain management which includes a Thoracic Epidural plus Intraoperative Intercostal Cryoanalgesia
Study: NCT01826162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acetate or placebo infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acetate or placebo infusion
Study: NCT00976534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1386
Description: 90 mg, capsules, oral, during 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules, oral, during 3 weeks
Study: NCT00931307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon A contact lens
Description: Silicone hydrogel, spherical, soft contact lens
Study: NCT04196166

Intervention type: OTHER
Intervention: preoperative blood tests

Intervention type: OTHER
Intervention: preoperative blood tests
Study: NCT06054048

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine
Description: Web Real-Time Communication (WebRTC), which enables a peer-to-peer connectivity. Communication platform for all TCs was the software CompuGroup Medical Electronic Visit (CGM ELVI), which provides end-to-end encrypted video conferencing between physicians and their patients.
Study: NCT01740583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous annuloplasty
Description: plication of the mitral valve annulus
Study: NCT00808600

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: resource-activating behavioural training programme
Description: Stepwise intervention based on the principles of resource-activating training (RAT) applied to the needs of patients in the process after lung transplantation.~Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Continued resource-activation and transfer by means of internet-based interventions (1 per 2 weeks) as well as personal interventions by trained nurses and a clinical psychologist during regular out-patient visits (approx. 4 times per year) over one year immediately following rehabilitation. Interventions focus on strengthening individual and interpersonal resources for well-being, psychoeducation, stress management and coping with illness. Phase 3: Termination and transfer, including a detailed medical report.
Study: NCT04626375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bioarginine
Description: In the Bioarginine group the partecipants take bioarginine (2 vials per os of 1.66 g every 12 hours) for 4 week
Study: NCT02203604

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01734109

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Quantum Negative Pressure Wound Therapy Device
Description: To compare the additional benefit of Quantum Negative pressure wound therapy device with and without simultaneous irrigation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Quantum Negative Pressure Wound Therapy Device
Description: To compare the additional benefit of Quantum Negative pressure wound therapy device with and without simultaneous irrigation.
Study: NCT02182726

Intervention type: DRUG
Intervention: MOBEC
Study: NCT03641235

Intervention type: BIOLOGICAL
Intervention: Sputum collection
Description: Analysis of Sputum collection
Study: NCT03771391

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PKU Sphere
Description: PKU sphere is a powdered, low phenylalanine protein substitute containing a balanced mix of casein glycomacropeptide (GMP) isolate, essential and non-essential amino acids, carbohydrate, vitamins, minerals and docosahexaenoic acid (DHA). With sugar and sweetener.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PKU Sphere
Description: PKU sphere is a powdered, low phenylalanine protein substitute containing a balanced mix of casein glycomacropeptide (GMP) isolate, essential and non-essential amino acids, carbohydrate, vitamins, minerals and docosahexaenoic acid (DHA). With sugar and sweetener.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PKU Sphere
Description: PKU sphere is a powdered, low phenylalanine protein substitute containing a balanced mix of casein glycomacropeptide (GMP) isolate, essential and non-essential amino acids, carbohydrate, vitamins, minerals and docosahexaenoic acid (DHA). With sugar and sweetener.
Study: NCT02439593

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiotherapy (CTRT)
Description: CTRT arm: Locoregional radiotherapy along with concurrent weekly gemcitabine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermochemoradiotherapy (CTRTHT)
Description: Locoregional hyperthermia with concurrent chemoradiotherapy with weekly gemcitabine
Study: NCT04089657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib 500mg qd, oral, taken half an hour after a meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg intravenously on day 1
Study: NCT04121091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole Pill
Description: Add-on pramipexole
Study: NCT01831297

Intervention type: DEVICE
Intervention: measurement of blood pressure
Description: measurement of pulse wave velocity
Study: NCT01396252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836
Description: Tablets, Oral, 0.5 mg, Once daily, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836
Description: Tablets, Oral, 1 mg, Once daily, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836
Description: Tablets, Oral, 2 mg, Once daily, 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BMS-820836
Description: Tablets, Oral, 0 mg, Once daily, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836
Description: Tablets, Oral, (initiated at 1 mg and dose escalated to the target dose of 2 mg), Once daily, 14 days
Study: NCT05785273

Intervention type: DEVICE
Intervention: Pupillometer
Description: 1st pupil evaluation between induction of general anesthesia and onset of surgery. After incision, at least 3 pupil evaluations are performed. Measurements are spaced 15 minutes apart and also taken at least 10 minutes after any variation in drugs dosage

Intervention type: DEVICE
Intervention: Pupillometer
Description: 1st pupil evaluation between induction of general anesthesia and onset of surgery. After incision, at least 3 pupil evaluations are performed. Measurements are spaced 15 minutes apart and also taken at least 10 minutes after any variation in drugs dosage
Study: NCT04626375

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: In the Placebo group the participants take bio-arginine (2 vials per os of 1.66 g every 12 hours) for 4 week
Study: NCT03692039

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: M-pro files in rotating motion
Description: An endodontic file that has controlled memory properties

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ProTaper Next files in rotating motion
Description: An endodontic file that has an off center mass of rotation
Study: NCT04726683

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling and placebo injection
Description: Dry Needling is applied with a filiform needle to penetrate the skin and stimulate the underlying myofascial trigger point of the masseter muscle. Dry needling is combined with placebo injection, in which the tip of a beveled needle is cut and the process of injection is simulated without penetrating the skin.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection and placebo dry needling
Description: Lidocaine injection applied in the myofascial trigger point of the masseter muscle. Lidocaine injection is combined with placebo dry needling, in which the tip of a filiform needle is cut and the dry needling technique simulated without penetrating the skin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling and injection
Description: Dry Needling is applied with a filiform needle to penetrate the skin and stimulate the underlying myofascial trigger point of the masseter muscle. Dry needling is combined with lidocaine injection applied in the myofascial trigger point of the masseter muscle.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo dry needling and placebo injection
Description: Placebo dry needling, in which the tip of a filiform needle is cut and the dry needling technique simulated without penetrating the skin. Placebo dry needling is combined with placebo injection, in which the tip of a beveled needle is cut and the process of injection is simulated without penetrating the skin
Study: NCT00740207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VISIPAQUE 270
Description: VISIPAQUE 270 (Iodixanol Injection) is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isovue 250
Description: ISOVUE-250 (Iopamidol Injection) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
Study: NCT04358302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pillsy
Description: The electronic pill bottle cap, Pillsy, and its accompanying software application provides reminders to take a scheduled dosage of medication via bottle cap alerts and smartphone push notifications, text messages, and/or automated phone calls. The Pillsy application records dosing dispense date and time when the user opens the bottle. During the first 2 weeks of the trial, the electronic notifications will be disabled to determine a baseline measure of adherence. Within 1 day after Visit 2, the electronic notifications will be turned on for all participants, resulting in a series of alerts (via electronic pill bottle cap alerts and smartphone push notifications, text message, and/or automated phone calls).~The electronic pill bottle cap, Pillsy, is a commercially available device marketed to consumers. The electronic pill bottle cap does not capture or store PHI. Quick tips on how to use Pillsy can be found at https://www.pillsy.com/instructions
Study: NCT02471014

Intervention type: DRUG
Intervention: Pneumovax 23
Description: All participants will receive a single 0.5 mL Pneumovax 23 intramuscular vaccine at baseline.

Intervention type: DRUG
Intervention: Pneumovax 23
Description: All participants will receive a single 0.5 mL Pneumovax 23 intramuscular vaccine at baseline.
Study: NCT01753570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424
Description: MP-424: 750mg every 8 hours (q8h) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424
Description: MP-424: 750mg every 8 hours (q8h) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV(24 weeks)
Description: RBV: 600 - 1000mg/day based on body weight for 24 weeks
Study: NCT02471014

Intervention type: OTHER
Intervention: Blood tests
Description: All participants will have two 50 milliliter blood draws: at baseline and up to 6 weeks later.

Intervention type: OTHER
Intervention: Blood tests
Description: All participants will have two 50 milliliter blood draws: at baseline and up to 6 weeks later.

Intervention type: OTHER
Intervention: Questionnaires
Description: All participants will answer the following questionnaires:~UCLA Loneliness Scale Questionnaire will be used to measure a difference between the groups.~Perceived Stress Scale-10 Questionnaire will be used to measure a difference between the groups.~Interpersonal Support Evaluation List-12 will be used to measure a difference between the groups Life Orientation Test-Revised will be used to measure a difference between the groups.

Intervention type: OTHER
Intervention: Questionnaires
Description: All participants will answer the following questionnaires:~UCLA Loneliness Scale Questionnaire will be used to measure a difference between the groups.~Perceived Stress Scale-10 Questionnaire will be used to measure a difference between the groups.~Interpersonal Support Evaluation List-12 will be used to measure a difference between the groups Life Orientation Test-Revised will be used to measure a difference between the groups.
Study: NCT03030417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMP744
Description: Indenoisoquinolines, such as LMP744, are potent inhibitors of the enzyme topoisomerase I (Top1). Top1 is necessary for transcription, replication, recombination, and the repair of double-strand deoxyribonucleic acid (DNA) breaks. It relaxes the supercoiled DNA by introducing a single-strand break, generating a free strand that rotates around the Top1-bound DNA complex. In the absence of external triggers, Top1-DNA cleavage complexes are generally short lived. Top1 inhibitors are potent anticancer agents because they stabilize the formation of the Top1-DNA cleavage complex in tumor cells, which induces DNA damage, delays DNA repair, and results in cell cycle arrest and apoptosis. LMP744 exhibited antitumor activity with lower toxicity than other agents in preclinical studies. Treatment of patients with LMP744 is expected to reduce tumor burden at doses that are well-tolerated.
Study: NCT03030417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Anti-emetic for nausea or vomiting.
Study: NCT04179188

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Classical Bariatric surgery (ring, Sleeve gastrectomy or Bypass)

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Classical Bariatric surgery (ring, Sleeve gastrectomy or Bypass)
Study: NCT00808600

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Relaxation training
Description: Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Regular relaxation training after rehabilitation by self-guided relaxation compact disk and accompanying worksheets.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Relaxation training
Description: Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Regular relaxation training after rehabilitation by self-guided relaxation compact disk and accompanying worksheets.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intensified anaerobic exercise training
Description: Phase 1: Recruitment and initiation of intensified and individualised aerobic/anaerobic exercise training based on determination of aerobic/anaerobic threshold during rehabilitation in the rehabilitation centre Fallingbostel. During rehabilitation daily training sessions with a duration of 30 minutes each are performed under medical supervision. Phase 2: Home training on an IT-assisted ergometer 3.5 times a week with interval exercise intensity above the anaerobic threshold. Work load and heart rate are stored by an ergometer-chip, lung function analyses are performed and should be transferred via phone-based telemetry. Exercise training intensities will be adapted monthly, corresponding to training results. At regular 3 months visits to the outpatient clinic a medical examination is carried out. Moreover, according to the actual functional state of the patient estimated 3 monthly training work load will be adjusted. Phase 3: Termination, evaluation after a period of 12 months.
Study: NCT03030417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Persistent nausea or vomiting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Persistent nausea or vomiting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diphenoxylate hydrocholoride (HCL) + Atropine Sulfate
Description: Diphenoxylate hydrocholoride (HCL) 2.5 mg + Atropine Sulfate 0.025 mg/tablet for diarrhea.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Antidiarrheal. 4mg by mouth (PO) after first unformed stool and 2mg PO every 2 hours as long as unformed stools continue. No more than 16mg during a 24-hour period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine 50 mg intravenous (IV) for allergic reaction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Steroid
Description: For allergic reaction at discretion of principal investigator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: For allergic reaction at discretion of principal investigator.
Study: NCT02962661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Given standard of care
Study: NCT00314275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary Artery Stenting
Description: Drug eluting stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endeavor
Description: Drug eluting stent
Study: NCT00623688

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metered Dose Inhaler & Optichamber Advantage Valve Holding Chamber (VHC)
Description: Albuterol is delivered by metered dose inhaler with valved holding chamber. For children less than 6 years of age, a mask is also used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airlife Sidestream High Efficiency Nebulizer
Description: Albuterol is delivered as a mist mixed with normal saline using a nebulizer machine and face mask or mouth piece.
Study: NCT02962661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Given standard of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Given standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cell Transplantation
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cell Transplantation
Description: Given transendocardially
Study: NCT02553057

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical ventilation
Study: NCT02491983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Study: NCT04204707

Intervention type: OTHER
Intervention: PROMS
Description: Patient Reported Outcomes after different types of surgery for rectal endometriosis

Intervention type: OTHER
Intervention: PROMS
Description: Patient Reported Outcomes after different types of surgery for rectal endometriosis